Ascendis Pharma A/S (NASDAQ:ASND) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Ascendis Pharma A/S (NASDAQ:ASND) has been given a consensus rating of “Moderate Buy” by the eight analysts that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $173.25.

A number of research firms recently commented on ASND. JPMorgan Chase & Co. lifted their price target on Ascendis Pharma A/S from $165.00 to $167.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 2nd. Wedbush raised their target price on shares of Ascendis Pharma A/S from $207.00 to $225.00 and gave the stock an “outperform” rating in a report on Thursday, February 8th. Cantor Fitzgerald reissued an “overweight” rating and issued a $173.00 target price on shares of Ascendis Pharma A/S in a report on Monday, April 1st. Citigroup raised their target price on shares of Ascendis Pharma A/S from $146.00 to $182.00 and gave the stock a “buy” rating in a report on Thursday, February 8th. Finally, Wells Fargo & Company raised their target price on shares of Ascendis Pharma A/S from $196.00 to $260.00 and gave the stock an “overweight” rating in a report on Friday, March 15th.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of hedge funds have recently made changes to their positions in ASND. Envestnet Asset Management Inc. raised its holdings in shares of Ascendis Pharma A/S by 14.4% during the first quarter. Envestnet Asset Management Inc. now owns 2,246 shares of the biotechnology company’s stock valued at $264,000 after buying an additional 282 shares during the last quarter. Rice Hall James & Associates LLC raised its holdings in shares of Ascendis Pharma A/S by 35.1% during the first quarter. Rice Hall James & Associates LLC now owns 134,900 shares of the biotechnology company’s stock valued at $15,832,000 after buying an additional 35,039 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Ascendis Pharma A/S by 20.5% during the first quarter. Bank of New York Mellon Corp now owns 289,344 shares of the biotechnology company’s stock valued at $33,958,000 after buying an additional 49,298 shares during the last quarter. BlackRock Inc. raised its holdings in shares of Ascendis Pharma A/S by 25.3% during the first quarter. BlackRock Inc. now owns 401,084 shares of the biotechnology company’s stock valued at $47,070,000 after buying an additional 80,988 shares during the last quarter. Finally, Affinity Asset Advisors LLC bought a new stake in shares of Ascendis Pharma A/S during the first quarter valued at approximately $14,083,000.

Ascendis Pharma A/S Stock Performance

NASDAQ:ASND opened at $145.23 on Tuesday. The company has a market capitalization of $8.46 billion, a price-to-earnings ratio of -15.70 and a beta of 0.50. Ascendis Pharma A/S has a one year low of $66.03 and a one year high of $161.00. The stock has a 50-day simple moving average of $149.10 and a 200 day simple moving average of $123.28.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Wednesday, February 7th. The biotechnology company reported ($1.66) EPS for the quarter, topping analysts’ consensus estimates of ($2.15) by $0.49. The business had revenue of $148.62 million during the quarter, compared to the consensus estimate of $97.02 million. Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 180.61%. On average, equities research analysts forecast that Ascendis Pharma A/S will post -4.18 EPS for the current fiscal year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.